Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group..

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50.

PMID:
15097150
2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
4.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
5.

Efavirenz: a pharmacoeconomic review of its use in HIV infection.

Plosker GL, Perry CM, Goa KL.

Pharmacoeconomics. 2001;19(4):421-36. Review.

PMID:
11383758
6.

Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.

Palacios R, Aguilar I, Hidalgo A, Santos J.

Expert Rev Anti Infect Ther. 2006 Dec;4(6):965-71. Review.

PMID:
17181413
7.

Perspectives on HAART: switch maintenance therapy.

Leen CL.

Int J STD AIDS. 2003 Sep;14(9):577-82. Review.

PMID:
14511491
8.

Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.

Pillay P, Ford N, Shubber Z, Ferrand RA.

PLoS One. 2013 Jul 22;8(7):e68995. doi: 10.1371/journal.pone.0068995. Review.

9.

Efavirenz-associated gynecomastia: report of five cases and review of the literature.

Jover F, Cuadrado JM, Roig P, Rodríguez M, Andreu L, Merino J.

Breast J. 2004 May-Jun;10(3):244-6. Review.

PMID:
15125753
10.

Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure.

Rutherford GW, Anglemyer A, Easterbrook PJ, Horvath T, Vitoria M, Penazzato M, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S161-9. doi: 10.1097/QAD.0000000000000236. Review.

PMID:
24849476
11.

Neuropsychiatric side effects of efavirenz therapy.

Arendt G, de Nocker D, von Giesen HJ, Nolting T.

Expert Opin Drug Saf. 2007 Mar;6(2):147-54. Review.

PMID:
17367260
12.
13.

Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review.

Wainberg MA, Clotet B.

AIDS Patient Care STDS. 2007 Sep;21(9):609-20. Review.

PMID:
17919088
14.

A risk-benefit assessment of HIV protease inhibitors.

Moyle GJ, Gazzard BG.

Drug Saf. 1999 Apr;20(4):299-321. Review.

PMID:
10230580
15.

The impact of pharmacogenetics on HIV therapy.

Mahungu TW, Johnson MA, Owen A, Back DJ.

Int J STD AIDS. 2009 Mar;20(3):145-51. doi: 10.1258/ijsa.2008.008369. Review.

PMID:
19255258

Supplemental Content

Support Center